284 related articles for article (PubMed ID: 28262558)
1. Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells.
Tumber A; Nuzzi A; Hookway ES; Hatch SB; Velupillai S; Johansson C; Kawamura A; Savitsky P; Yapp C; Szykowska A; Wu N; Bountra C; Strain-Damerell C; Burgess-Brown NA; Ruda GF; Fedorov O; Munro S; England KS; Nowak RP; Schofield CJ; La Thangue NB; Pawlyn C; Davies F; Morgan G; Athanasou N; Müller S; Oppermann U; Brennan PE
Cell Chem Biol; 2017 Mar; 24(3):371-380. PubMed ID: 28262558
[TBL] [Abstract][Full Text] [Related]
2. Characterization of a Linked Jumonji Domain of the KDM5/JARID1 Family of Histone H3 Lysine 4 Demethylases.
Horton JR; Engstrom A; Zoeller EL; Liu X; Shanks JR; Zhang X; Johns MA; Vertino PM; Fu H; Cheng X
J Biol Chem; 2016 Feb; 291(6):2631-46. PubMed ID: 26645689
[TBL] [Abstract][Full Text] [Related]
3. KDOAM-25 Overcomes Resistance to MEK Inhibitors by Targeting KDM5B in Uveal Melanoma.
Zhang H; Liu X; Chen Y; Xu R; He S
Biomed Res Int; 2022; 2022():1556485. PubMed ID: 36212716
[TBL] [Abstract][Full Text] [Related]
4. Studies of H3K4me3 demethylation by KDM5B/Jarid1B/PLU1 reveals strong substrate recognition in vitro and identifies 2,4-pyridine-dicarboxylic acid as an in vitro and in cell inhibitor.
Kristensen LH; Nielsen AL; Helgstrand C; Lees M; Cloos P; Kastrup JS; Helin K; Olsen L; Gajhede M
FEBS J; 2012 Jun; 279(11):1905-14. PubMed ID: 22420752
[TBL] [Abstract][Full Text] [Related]
5. The KDM5 family of histone demethylases as targets in oncology drug discovery.
Rasmussen PB; Staller P
Epigenomics; 2014 Jun; 6(3):277-86. PubMed ID: 25111482
[TBL] [Abstract][Full Text] [Related]
6. Identification of in vitro JMJD lysine demethylase candidate substrates via systematic determination of substrate preference.
Hoekstra M; Biggar KK
Anal Biochem; 2021 Nov; 633():114429. PubMed ID: 34678252
[TBL] [Abstract][Full Text] [Related]
7. Structural analysis of human KDM5B guides histone demethylase inhibitor development.
Johansson C; Velupillai S; Tumber A; Szykowska A; Hookway ES; Nowak RP; Strain-Damerell C; Gileadi C; Philpott M; Burgess-Brown N; Wu N; Kopec J; Nuzzi A; Steuber H; Egner U; Badock V; Munro S; LaThangue NB; Westaway S; Brown J; Athanasou N; Prinjha R; Brennan PE; Oppermann U
Nat Chem Biol; 2016 Jul; 12(7):539-45. PubMed ID: 27214403
[TBL] [Abstract][Full Text] [Related]
8. Identification of potent, selective KDM5 inhibitors.
Gehling VS; Bellon SF; Harmange JC; LeBlanc Y; Poy F; Odate S; Buker S; Lan F; Arora S; Williamson KE; Sandy P; Cummings RT; Bailey CM; Bergeron L; Mao W; Gustafson A; Liu Y; VanderPorten E; Audia JE; Trojer P; Albrecht BK
Bioorg Med Chem Lett; 2016 Sep; 26(17):4350-4. PubMed ID: 27476424
[TBL] [Abstract][Full Text] [Related]
9. Domain architecture and protein-protein interactions regulate KDM5A recruitment to the chromatin.
Kataria A; Tyagi S
Epigenetics; 2023 Dec; 18(1):2268813. PubMed ID: 37838974
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design and discovery of potent and selective KDM5 inhibitors.
Nie Z; Shi L; Lai C; O'Connell SM; Xu J; Stansfield RK; Hosfield DJ; Veal JM; Stafford JA
Bioorg Med Chem Lett; 2018 May; 28(9):1490-1494. PubMed ID: 29627262
[TBL] [Abstract][Full Text] [Related]
11. An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.
Vinogradova M; Gehling VS; Gustafson A; Arora S; Tindell CA; Wilson C; Williamson KE; Guler GD; Gangurde P; Manieri W; Busby J; Flynn EM; Lan F; Kim HJ; Odate S; Cochran AG; Liu Y; Wongchenko M; Yang Y; Cheung TK; Maile TM; Lau T; Costa M; Hegde GV; Jackson E; Pitti R; Arnott D; Bailey C; Bellon S; Cummings RT; Albrecht BK; Harmange JC; Kiefer JR; Trojer P; Classon M
Nat Chem Biol; 2016 Jul; 12(7):531-8. PubMed ID: 27214401
[TBL] [Abstract][Full Text] [Related]
12. Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.
Gale M; Sayegh J; Cao J; Norcia M; Gareiss P; Hoyer D; Merkel JS; Yan Q
Oncotarget; 2016 Jun; 7(26):39931-39944. PubMed ID: 27224921
[TBL] [Abstract][Full Text] [Related]
13. Drawing a line between histone demethylase KDM5A and KDM5B: their roles in development and tumorigenesis.
Yoo J; Kim GW; Jeon YH; Kim JY; Lee SW; Kwon SH
Exp Mol Med; 2022 Dec; 54(12):2107-2117. PubMed ID: 36509829
[TBL] [Abstract][Full Text] [Related]
14. Histone H3K4 demethylases are essential in development and differentiation.
Benevolenskaya EV
Biochem Cell Biol; 2007 Aug; 85(4):435-43. PubMed ID: 17713579
[TBL] [Abstract][Full Text] [Related]
15. Assessing histone demethylase inhibitors in cells: lessons learned.
Hatch SB; Yapp C; Montenegro RC; Savitsky P; Gamble V; Tumber A; Ruda GF; Bavetsias V; Fedorov O; Atrash B; Raynaud F; Lanigan R; Carmichael L; Tomlin K; Burke R; Westaway SM; Brown JA; Prinjha RK; Martinez ED; Oppermann U; Schofield CJ; Bountra C; Kawamura A; Blagg J; Brennan PE; Rossanese O; Müller S
Epigenetics Chromatin; 2017; 10():9. PubMed ID: 28265301
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia induces rapid changes to histone methylation and reprograms chromatin.
Batie M; Frost J; Frost M; Wilson JW; Schofield P; Rocha S
Science; 2019 Mar; 363(6432):1222-1226. PubMed ID: 30872526
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia induces trimethylated H3 lysine 4 by inhibition of JARID1A demethylase.
Zhou X; Sun H; Chen H; Zavadil J; Kluz T; Arita A; Costa M
Cancer Res; 2010 May; 70(10):4214-21. PubMed ID: 20406991
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy.
Miyake Y; Itoh Y; Hatanaka A; Suzuma Y; Suzuki M; Kodama H; Arai Y; Suzuki T
Bioorg Med Chem; 2019 Mar; 27(6):1119-1129. PubMed ID: 30745098
[TBL] [Abstract][Full Text] [Related]
19. Impaired removal of H3K4 methylation affects cell fate determination and gene transcription.
Lussi YC; Mariani L; Friis C; Peltonen J; Myers TR; Krag C; Wong G; Salcini AE
Development; 2016 Oct; 143(20):3751-3762. PubMed ID: 27578789
[TBL] [Abstract][Full Text] [Related]
20. Cross-talk between Lysine-Modifying Enzymes Controls Site-Specific DNA Amplifications.
Mishra S; Van Rechem C; Pal S; Clarke TL; Chakraborty D; Mahan SD; Black JC; Murphy SE; Lawrence MS; Daniels DL; Whetstine JR
Cell; 2018 Aug; 174(4):803-817.e16. PubMed ID: 30057114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]